Department of Otolaryngology-Head and Neck Surgery, Galilee Medical Center, Nahariya, Israel.
Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
Int Forum Allergy Rhinol. 2021 Feb;11(2):174-194. doi: 10.1002/alr.22668. Epub 2020 Aug 6.
Epiphora due to refractory bicanalicular obstructions is typically managed by conjunctivodacryocystorhinostomy (CDCR) with or without the assistance of nasal endoscopy. However, the evidence for its benefit is unclear.
A systematic review of the literature on the treatment of epiphora by CDCR was performed (March 1, 2018). All studies reporting original data on patients suffering from epiphora treated with CDCR surgery were included. Primary outcomes were success and satisfaction rates. Secondary outcomes were CDCR complications. A comparison was made between the results obtained in patients undergoing CDCR with vs without assistance of nasal endoscopy.
Fifty-four studies representing information on 2555 CDCR procedures were included in the systematic review. All the studies are case series, most of them retrospective. Lester Jones tube (LJT) is the most commonly used in CDCR (66.7%). The overall success rate with all studies included (n = 2555) was 88.9%; 90.8% (n = 890) in CDCR with assistance of nasal endoscope and 87.7% (n = 1575) in the non-endoscopic approach. The overall "tube displacement" rate, the most common complication, was 24.5% (n = 2522), 20.8% (n = 1575) tube displacement in CDCR with assistance of nasal endoscope vs 26.7% (n = 1575) in the non-endoscopic approach. Only 3 studies (5.5%) used patient-reported outcome measures (PROMs) to evaluate epiphora improvement. Due to the low level of evidence and the high bias of the studies, a meta-analysis was not performed.
Based on the data available in the literature, CDCR is considered an effective procedure for treating epiphora due to proximal obstruction. Controlled and qualitative studies are needed to clarify the significance of the endoscope's contribution to CDCR.
由于难治性双管阻塞引起的溢泪症通常通过结膜囊鼻腔吻合术(CDCR)治疗,可辅以或不辅以鼻内窥镜。然而,其益处的证据并不明确。
对 CDCR 治疗溢泪症的文献进行系统评价(2018 年 3 月 1 日)。所有报告接受 CDCR 手术治疗溢泪症的患者原始数据的研究均包括在内。主要结果是成功率和满意度。次要结果是 CDCR 并发症。比较了接受和不接受鼻内窥镜辅助的 CDCR 患者的结果。
54 项研究代表了 2555 例 CDCR 手术的信息,被纳入系统评价。所有研究均为病例系列研究,其中大多数为回顾性研究。LesterJones 管(LJT)是 CDCR 中最常用的(66.7%)。纳入的所有研究(n=2555)的总体成功率为 88.9%;鼻内窥镜辅助 CDCR 的成功率为 90.8%(n=890),非内窥镜方法的成功率为 87.7%(n=1575)。最常见的并发症“管移位”的总体发生率为 24.5%(n=2522),鼻内窥镜辅助 CDCR 的管移位率为 20.8%(n=1575),非内窥镜方法的管移位率为 26.7%(n=1575)。仅有 3 项研究(5.5%)使用患者报告的结局测量(PROMs)来评估溢泪改善情况。由于证据水平低且研究偏倚高,因此未进行荟萃分析。
根据文献中的现有数据,CDCR 被认为是治疗近端阻塞引起溢泪症的有效方法。需要进行对照和定性研究,以阐明内窥镜对 CDCR 的贡献的意义。